Journal
CLINICAL INFECTIOUS DISEASES
Volume 37, Issue 9, Pages 1234-1243Publisher
OXFORD UNIV PRESS INC
DOI: 10.1086/378807
Keywords
-
Categories
Funding
- NIAID NIH HHS [U01 AI38855, U01 AI38858] Funding Source: Medline
Ask authors/readers for more resources
This multicenter, randomized, open-label phase 3 clinical trial compared the safety and efficacy of 3 clarithromycin-containing combination regimens for the treatment of disseminated Mycobacterium avium complex( MAC) disease in persons with acquired immunodeficiency syndrome. A total of 160 eligible patients with bacteremic MAC disease were randomized to receive clarithromycin with either ethambutol (C+E), rifabutin (C+R), or both (C+E+R) for 48 weeks. After 12 weeks of treatment, the proportion of subjects with a complete microbiologic response was not statistically significantly different among treatment arms: the proportion was 40% in the C+E group, 42% in the C+R group, and 51% in the C+E+R group (P = .454). The proportion of patients with complete or partial responses who experienced a relapse while receiving C+R (24%) was significantly higher than that of patients receiving C+E+R (6%; P = .027) and marginally higher than that of patients receiving C+E (7%; Pp. 027). Subjects in the C+E+R group had improved survival, compared with the C+E group ( hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.23-0.83) and the C+R group ( HR, 0.49; 95% CI, 0.26-0.92).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available